Put the article in perspective folks......first, the article indicates that Kreigsman sold shares of GALE, not CYTR. The only bash against CYTR is the accusation that they paid SA to write positive articles (pump articles). You can't all tell me that TONS of companies don't pay for positive press.....it happens in EVERY industry! What you have to look at though is the fact that the FDA would NEVER allow CYTR to extend dosing of patients beyond the allowed 6 cycles that they gave DOX if they didn't do some major DD to make sure that the facts and positives about Aldox were indeed correct. So, you have to look past the fluffy articles at the real facts and the real data, and do your own DD.
If so, I will buy more. The stock promotion campaign does not affect Jeffries' and Oppenheimer's due diligence to price CYTR's secondary at $6.50 per share. Buying at $6.20 is a gift to longs, especially with aldox Phase II results and the FDA's decision to all Phase III aldox trials to extend dosage until PFA. I am a buyer here.
CytRx announced it has received approval from the FDA to continue dosing patients with aldoxorubicin until disease progression in a planned pivotal, global Phase 3 clinical trial with aldoxorubicin as a second-line treatment for soft tissue sarcomas. The clinical trial is scheduled to begin this quarter. For purposes of the clinical trial, disease progression is defined as an increase in the size of measurable tumors by 20% or the development of a new tumor lesion.
with that FDA approval , while anything is possible,,